Parkinson`s Conferences | Parkinsonism conferences | Neurology conferences | Movement Disorders | New York | USA

Theme: Improving the care of patients with Parkinsonâ€™s disease and Movement disorders through Translating Science to Clinical Practice

Parkinsons 2018

Scientific Program

Renowned Speakers

Hamada Zehry
Department of Neurology, Faculty of Medicine, Al-Azhar University,
Egypt

Rajendra D. Badgaiyan
University of Richmond
USA

Susan Scanland
Dementia ConnectionÂ® LLC,
USA

John M. Baumann
University of Louisville
USA

Harish C. Pant
Laboratory of Neurochemistry, NINDS
USA

A.V. Srinivasan
Dr. M.G.R. Medical University
India

Tyrone Genade
Northwestern College
USA

Mira Ambrus
University of A Coruna
Spain

Azza A Ali
Al-Azhar University
Egypt

Guy Hugues Fontaine
UniversitÃ© Pierre et Marie Curie
France

Bushra Ahmed

UK

Jean Barclay

USA

Junxia Xie

China

Viktorija Piscalkiene

Italy

Dasiel O. Borroto-Escuela

Sweden

Kohji Fukunaga

Japan

Jianfeng Lu

China

Hamada Ibrahim Zehry
Department of Neurology, Faculty of Medicine, Al-Azhar University, Egypt.
Egypt

Parkinsons 2018

Parkinson’s 2018 Organising Committee, invites all the participants from all over the world to attend the Parkinson’s 2018 conference entitled “5^th International conference on Parkinson's Disease and Movement Disorders” during October 19-20, 2018 in New York, USA. This gathering is predominantly will focus the most recent and energizing developments in each range of Parkinson’s research, and it will offer an exceptional opportunity for specialists from all over the world to meet, network, and distinguish with different scientific interactions.

Parkinson’s disease is a dynamic neurological disorder that influences how the individual moves, including how they talk and compose. This disease is caused by low dopamine levels. Various useful treatments, utilizing therapies (physiotherapy), surgery and medications have recognized neurological disorders and changes in the patient group. People with Parkinson’s disease also experience stiffness and they find abnormality in carrying out the movements as rapidly as before- this is known as bradykinesia.

The Parkinson’s disease market in US is expected to grow at a rate of 7.3% from sales of $1.1 billion in 2012 to $2.3 billion in 2022. Approximately 1 million adults in USA are suffering from Parkinson’s disease, from where 60,000 were diagnosed annually. An estimated of 40%-60% of PD patients mainly suffering from depression. United States is in the fourth position in considering the death of people due to Parkinson’s disease. African Americans have the highest death rate of 66.4% followed by whites of 64.6%, Hispanic with 55.4% and Asians with 50.8%. Parkinson’s disease strikes 50% more men than women. The economic burden of Parkinson’s disease on patients and their families in the U.S is about $14.4 billion.

Why to attend

Parkinson’s 2018 are the leading meeting dedicated to Neurologists and Neurosurgeons researchers with the theme “Improving the care of patients with Parkinson's disease and Movement disorders through Translating Science to clinical practice".

Goal of Parkinson’s2018 is to deliver an outstanding program for exchange of ideas and authoritative views by leading scientists which covers the entire spectrum of research in Parkinson’s Disease and Movement Disorders and share the cross-cultural experiences of various treatment procedures.

We strive to make Parkinson’s 2018 a success, with your support and high quality talks from both Parkinson’s disease and Movement Disorders communities. During the conference, we assure you that you will experience world class facilities and hospitality at the conference.

Approximately 1 million adults in USA are suffering from Parkinson’s disease, from where 60,000 were diagnosed annually. An estimated of 40%-60% of PD patients mainly suffering from depression. United States is in the fourth position in considering the death of people due to Parkinson’s disease.

Target audience: Neurologists, Psychiatrists, Psychologists, Neurosurgeon, Head of the department, Director, Industries, Delegates, Clinical, Physicians, Neuroscientists, Specialists, Community members, Lecturers and Students from Academia in the study of Parkinson disease, Professors, Researchers, Scientists, Students from Academia in the research of Neurology and Neuroscience, Nurses and Therapists.

Details of Parkinson Conferences 2018 in USA

Conference name	Venue	Date
Parkinson Conference 2018	NewYork City, USA	October 19-20,2018

On behalf of the Conference Organizing Committee, it is our heartiest welcome you to the “5^th International conference on Parkinson's Disease and Movement Disorders” during October 19-20, 2018 at New York, USA.

Parkinsons Disease 2018 is the leading gathering of neurologists, psychiatry, psychology researchers, and neurosurgeons with the theme of Movement Disorders across the Americas: Translating Science to Clinical Practice. Its main aim to deliver ideas for exchange of ideas and thoughts with the leading scientists which covers entire area of neurological disorder.

The objective of this session is to comprehend the inducement, Genesis and Diagnosis and prognosis including care giving of Parkinson’s disease and further hastening the revivification of Parkinson Disease.

Session on: Parkinson Disease

Parkinson's affliction is a dynamic issue of the sensory system that influences advancement. It develops gradually, at times starting with a barely distinguishable tremor in just a single hand. In any case, while a tremor may be the most surely understood indication of Parkinson's infection, the turmoil in like manner frequently causes strength or directing of advancement. In the early periods of Parkinson's disease, your face may demonstrate beside zero demeanours, or your arms may not swing when you walk. Your discourse may end up being fragile or slurred. Parkinson's disease signs compound as your condition propels after some time.

World Summit on Mindfulness, Philosophy and Stress Management, Aug 27-28, 2018 Boston,Massachusetts,USA; World Summit on Alzheimer’s Disease, Dementia Care Research and Awareness, Aug 31-Sept 01, 2018, Boston, USA; World Summit on Heart, Stroke & Neurological Disorders, Aug 31-September 01, 2018 Boston, Massachusetts,USA; 8th International Conference on Cognitive Science, Brain Disorders and Research, Sept 21-22, 2018, Philadelphia,USA; 3rd International Conference on Neuropsychiatry and Sleep Medicine, Sept 21-22, 2018, Philadelphia, USA; 8th International Conference on Neurology and Brain Disorder, Sept 26-27, 2018, Montreal, Canada; 5th International Conference on Parkinson’s Disease & Movement Disorders, Oct 19-20, 2018, New York, USA;

Related Associations and Societies:

USA and Canada: American Academy of Neurology, Movement Disorders Society, Parkinson Society Canada, The International Parkinson and Movement Disorder Society, Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN)

Europe: UK Parkinsons Action Network, European Neurological Society, European Parkinsons Disease Association, Danish Movement Disorder Society, Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia

Asia-Pacific and Middle East: Movement Disorder Society of Australia, Parkinson’s Disease and Movement Disorders Society of India, Austrian Parkinson’s Disease Society, Movement Disorder Society of Japan

Session on: Epidemiology of Parkinsons Disease

Parkinsons disease is one of the well-known age related neurodegenerative disorder, second in recurrence just to Alzheimer's disease. Parkinsons disease also causes extensive injury of the motor or sensory pathways extending beyond the pigmental brain stem nuclei. Although the disease symptoms can be controlled by Levodopa but the etiology of the Parkinsons disease remains obscure. In the United States half a million of people are diagnosed as having PD and it is predicted to be triple over next 50 years. PD appears to be slightly more in men than in women usually ranging from 1.2:1 ratio upto 1.5:1. The Parkinsons disease market in US is expected to grow at a rate of 7.3% from sales of $1.1 billion in 2012 to $2.3 billion in 2022. The population with Parkinsons disease incurred medical expenses of approximately $14.4 per year in United States. In U.S. 15% of people with PD were in the nursing homes as compared to 9 % are of all residents aged 75-84.

Related Associations and Societies:

USA and Canada: Parkinson’s Action Network (PAN), American Academy of Neurology, Movement Disorders Society, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson Society Canada, The International Parkinson and Movement Disorder Society, Canadian Movement Disorders Group

Europe: Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia, UK Parkinsons Action Network, Danish Movement Disorder Society, European Neurological Society, European Parkinsons Disease Association

Asia-Pacific and Middle East: Movement Disorder Society of Japan, Movement Disorder Society of Australia, Austrian Parkinson’s Disease Society, Parkinson’s Disease and Movement Disorders Society of India

Session on: Neurocognitive and Neuromuscular Disorders

Neurocognitive disorder is a reduction of cognitive function in one of these areas, especially when physical changes can be seen to have occurred in the cerebrum, for example, after neurological disease, brain injury or drug use. It occurs due to PD with behaviour disturbance. According to the recent projects of the United Nations between 2000 to 2050 the people over 65 years of age will exceed 1.1 billion worldwide. For estimation by 2050 Parkinson’s disease will be $285 billion in the USA.

Neuromuscular disorder is a disease that affects the peripheral nervous system which includes muscles, nerve-muscle junction, and peripheral nerves in the limbs and motor nerve cells in the spinal cord. Approximately 5600 people in the US are diagnosed with ALS each year. In US each year 750,000 people experience stroke, 11000 people suffer spinal cord injury, 500,000 people suffering from cerebral palsy, 270,000 with multiple sclerosis and 5.3 million with the after affects of a traumatic brain injury and amyotrophic lateral sclerosis.

Related Associations and Societies:

USA and Canada: Canadian Movement Disorders Group, Parkinson’s Action Network (PAN), The International Parkinson and Movement Disorder Society, American Academy of Neurology, Movement Disorders Society, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson Society Canada

Europe: European Parkinsons Disease Association, Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia, UK Parkinsons Action Network, Danish Movement Disorder Society, European Neurological Society

Asia-Pacific and Middle East: Parkinson’s Disease and Movement Disorders Society of India, Movement Disorder Society of Japan, Movement Disorder Society of Australia, Austrian Parkinson’s Disease Society

Session on: Alzheimer's Disease & Dementia

Alzheimer's is caused by cerebrum cell demise. It is a neurological issue in which the demise of cerebrum cells causes memory misfortune and intellectual decrease. The aggregate size of the cerebrum contracts in Alzheimer's, nerve cells and associations in the tissue logically lessened, which can't be seen or tried in the living mind influenced by Alzheimer's ailment, posthumous/post-mortem examination will dependably demonstrate little incorporations in the nerve tissues, called as plaques and tangles. Plaques are found between the diminishing cells in the mind - from the development of a protein called beta (amyloid plaques). The tangles exist in the mind neurons, from a breaking down of second protein, called tau.

Around the world, with Dementia or Related issue almost 44 million individuals have endured in 2015,past outcomes demonstrated 35.66 million populace lived with dementia worldwide in year 2010, with numbers anticipated that would about twofold every twenty years, to 65.7 million out of 2030 and 115.4 million out of 2050. In 2010, fifty eight for each penny of all populace with dementia lived in nations with lower or direct livelihoods, with this extent expected to ascend to 63% till 2030 and 71% by 2050.

Related Associations and Societies:

USA and Canada: Parkinson Society Canada, Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN), The International Parkinson and Movement Disorder Society, American Academy of Neurology, Movement Disorders Society

Europe: European Neurological Society, European Parkinsons Disease Association, Danish Movement Disorder Society, Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia, UK Parkinsons Action Network

Asia-Pacific and Middle East: Austrian Parkinson’s Disease Society, Parkinson’s Disease and Movement Disorders Society of India, Movement Disorder Society of Japan, Movement Disorder Society of Australia

Session on: Risk Factors of Parkinsons disease

Risk factor for the Parkinsons disease mainly depends on age, hereditary, sex and exposure to toxins. Men are more affected than women; 25%-45% are caused by the loss of dopamine which causes rigid movements. Advancing age is a factor that is more consistently associated with an increase in the Parkinsons disease; only 5%-10% of people get PD before age of 40. It involve some of the symptoms like anxiety, cognitive problems, tremor or shaking, depression, trouble sleeping, low voice, loss of smell etc. Now a day’s Head injury and Gene variation is also a factor for Parkinsons disease.

Related Associations and Societies:

USA and Canada: Movement Disorders Society, Parkinson Society Canada, Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN), The International Parkinson and Movement Disorder Society, American Academy of Neurology

Europe: UK Parkinsons Action Network, Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia, European Neurological Society, European Parkinsons Disease Association, Danish Movement Disorder Society

Asia-Pacific and Middle East: Movement Disorder Society of Australia, Austrian Parkinson’s Disease Society , Parkinson’s Disease and Movement Disorders Society of India, Movement Disorder Society of Japan

Session on: Diagnostic and Neuroimaging for Parkinsons Disease

There is no direct treatment for Parkinsons disease as well any blood test or brain scan that confirms the diagnosis. Most PD treatments aim to restore the proper of the neurotransmitter acetylcholine and dopamine by increasing the dopamine levels. Treatment is totally based on the medical history and a neurological examination. At present there is no cure for PD, medications can lessen its symptoms and later stages surgery can be done. Parkinsons in the body; magnetic resonance imaging (MRI) is a test that produces very clear image of the human body without the use of X-rays. Instead of MRI uses a large magnet, radio waves, and a computer to produce these images. Medications are in three stages- first includes the drug which is known as levodopa which increase the dopamine in the brain, the second set of drugs eases some of the Parkinsons disease symptoms and the third set of drugs helps to control the non-motor symptoms including depression.

Related Associations and Societies:

USA and Canada: American Academy of Neurology, Movement Disorders Society, The International Parkinson and Movement Disorder Society, Parkinson Society Canada, Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN)

Europe: Danish Movement Disorder Society, UK Parkinsons Action Network, Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia, European Neurological Society, European Parkinsons Disease Association

Asia-Pacific and Middle East: Movement Disorder Society of Japan, Parkinson’s Disease and Movement Disorders Society of India, Movement Disorder Society of Australia, Austrian Parkinson’s Disease Society,

Session on: Pathophysiology and pharmacology

The most prominent pathological lesion observed in PD occurs in the basal ganglia of the brain’s extra-pyramidal system. Non-PD patients and without nigrostriatal degeneration develops dyskinesias in response to dopaminergic. It is caused by gradual loss of nerve cells in the brain area called nigra and also by low and falling dopamine levels. The worldwide prevalence of Parkinson disease is anticipated to grow to 2.89 million cases worldwide by 2022.

Related Associations and Societies:

USA and Canada: Parkinson’s Action Network (PAN), American Academy of Neurology, Movement Disorders Society, The International Parkinson and Movement Disorder Society, Parkinson Society Canada, Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation

Europe: European Neurological Society, European Parkinsons Disease Association, Danish Movement Disorder Society, UK Parkinsons Action Network, Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia

Asia-Pacific and Middle East: Austrian Parkinson’s Disease Society, Movement Disorder Society of Japan, Parkinson’s Disease and Movement Disorders Society of India, Movement Disorder Society of Australia

Session on: Parkinsons disease: Complications

Parkinsons disease is not thought to be a life threatening condition, but rather it has a vast effect of your personal satisfaction. With time, the sickness can bring about issues with speech, movement disorder, and brain functioning. The major complication in Parkinsons disease are blood pressure changes, depression, emotional changes, thinking difficulties, fatigue, sexual dysfunction, smell dysfunction, pain and sleep disorders.

Related Associations and Societies:

USA and Canada: Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN), American Academy of Neurology, Movement Disorders Society, The International Parkinson and Movement Disorder Society, Parkinson Society Canada, Canadian Movement Disorders Group

Europe: Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia, European Neurological Society, European Parkinsons Disease Association, Danish Movement Disorder Society, UK Parkinsons Action Network

Asia-Pacific and Middle East: Movement Disorder Society of Australia, Austrian Parkinson’s Disease Society, Movement Disorder Society of Japan, Parkinson’s Disease and Movement Disorders Society of India

Session on: Managing life with Parkinsons disease

It is important to develope a solid PD management plan because PD is a chronic disease. Managing with Parkinsons disease includes building a health care team with proper doctors, proper intake of medications, exercises, nutrition and sleep.

Related Associations and Societies:

USA and Canada: Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN), American Academy of Neurology, Movement Disorders Society, The International Parkinson and Movement Disorder Society, Parkinson Society Canada

Asia-Pacific and Middle East: Parkinson’s Disease and Movement Disorders Society of India, Movement Disorder Society of Australia, Austrian Parkinson’s Disease Society, Movement Disorder Society of Japan

Session on: Novel Insights and therapeutics for Parkinsons disease

Parkinsons disease is the essential growth driver of the worldwide Parkinsons disease therapeutics. Most mutations such as SNCA, PINK1, PARK2, PARK7, PLA2G6, FBXO7 and ATP13A2 are the rare cause of the disease and one particular mutation in LRRK2 has been found common in certain populations. The enzymatic function of the mitochondrial localized kinase PINK1 is thereby essential and delivers a fast production of Parkin from its uniform distribution in the cytoplasm to damaged mitochondria. The therapeutics of Parkinsons Disease includes designing a Clinical trial for Parkinson, Outcome of clinical trials in PSP, therapeutic options for mood, Cognition and Psychosis. Physical therapy cannot cure Parkinsons disease but therapy can help to compensate the changes brought about by the condition, physical therapy can help with balance problems, fatigue, pain, weakness and sometimes local heat application is produced with high frequency to relieve muscle aches and pain.

Related Associations and Societies:

USA and Canada: Parkinson Society Canada, Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN), American Academy of Neurology, Movement Disorders Society, The International Parkinson and Movement Disorder Society

Session on: Neural Transplantation

Neural transplantation is the transplantation of nerve cells and tissues into the brain and spinal cord. The cell replacement for Parkinsons Disease is based on two hypothesis- firstly the early symptoms of PD are dependent on the loss of the dopaminergic neurons in the nigrostriatal pathways and secondly the dopaminergic neurons and gathered into dopamine deficient striatum can replace those neurons which has been lost during the disease process and can reverse some extent of the major symptoms of Parkinson disease.

Related Associations and Societies:

USA and Canada: The International Parkinson and Movement Disorder Society, Parkinson Society Canada, Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN), American Academy of Neurology, Movement Disorders Society

Europe: European Parkinsons Disease Association, Danish Movement Disorder Society, UK Parkinsons Action Network, Italian Society for the study of Parkinson Disease, Extrapyramidal Diseases and Dementia, European Neurological Society

Session on: Paediatric Movement disorders

Paediatric movement disorder is a moderately new and developing field of child neurology. While hypokinetic scatters, for example, Parkinson disease prevails in adults. There are many genetic disease which cause secondary movement disorders in childhood. Propels in paediatric movement disorder have been made by solidifying movement disorder definitions, growing the range of clinical phenotypes, understanding genetic reasons for movement disorders, and thoroughly assessing treatment adequacy for normal movement disorders. The central nervous systems typically implicated in disorders of movement are the basal and frontal cortex. Five areas were highlighted these advances: consensus definitions, newly found PRRT2 mutation, clinical and genetic range of GLUT-1 lack and neurodegeneration with brain iron aggregation (NBIA) issue, and exhaustive behavioural interventions for tics (CBIT).

Related Associations and Societies:

USA and Canada: Movement Disorders Society, The International Parkinson and Movement Disorder Society, Parkinson Society Canada, Canadian Movement Disorders Group, Bachmann-Strauss Dystonia and Parkinson Foundation, Parkinson’s Action Network (PAN), American Academy of Neurology

Theme: Improving the care of patients with Parkinson’s disease and Movement disorders through Translating Science to Clinical Practice

On behalf of the Conference Series LTD, It is our heartiest welcome you to the “5^thInternational conference on Parkinson's Disease and Movement Disorders” during October 19-20, 2018 in New York, USA.

Importance and scope

Parkinson’s 2018 are conducted exclusively in support to worldwide neuro researchers. We endeavour to make Parkinson’s 2018 a grand success, with the support of high eminent talks from the neuro science and Parkinson’s disease communities. During the time, you spend at this congress; we promise you that we will provide you with world class facilities and hospitality.

Parkinson’s disease is a progressive disease of the nervous system set apart by tremor, muscle rigidity, and moderate, imprecise movement, chiefly affecting aged and elderly individuals. It is connected with degeneration of the basal ganglia of the brain and deficiency of the neurotransmitter dopamine.

Parkinson’s disease is a progressive neurological disorder which is caused due to neurodegeneration. About 10 million of people are suffering from Parkinson’s disease globally. The global prevalence in 2012 was approximately 2.18 million cases in worldwide where $1.15 billion in US market. The Parkinson’s disease market in US is expected to grow at a rate of 7.3% from sales of $1.1 billion in 2012 to $2.3 billion in 2022.Treatment market value is being expected to increase from $3.6 billion in 2012 to $5.3 billion in 2022. US- has the largest Parkinson’s disease therapeutics market share of 44% by 2022 which is expanding from 32% in 2012 and this will be followed by Japan, Brazil and Germany with shares of 13%, 11% and 10%. Approximately 1 million adults in USA are suffering from Parkinson’s disease, from where 60,000 were diagnosed annually. In the United Kingdom approximately 127,000 people are suffering from PD. Male got 50% higher risk than females, however 4 to 5% of the cases the sufferer is younger than 40 years and it is known as Young-onset Parkinson’s disease. NINDS funded about $90 million out of $135 million in NIH-supported PD research in USA.

The worldwide Parkinson's sickness showcase is divided on the premise of medication sort and topography. As per sedate sort, the market is portioned into, advertised and pipeline drugs. The showcased drugs are additionally divided into Levodopa, Dopamine agonists, Apomorphine, Glutamate rival, Anticholinergics, COMT inhibitors and MAO-B inhibitors. Topographically, the market is sectioned crosswise over four locales to be specific North America, Europe, Asia Pacific, and LAMEA.

Medicines for development issue are relied upon to be worth $3.2 billion out of 2012 and $4.8 billion out of 2017, a CAGR of 8.3%.

For more details, please visit: http://parkinsons.conferenceseries.com/

About the City

New York City is the most densely populated major city in United States and is located at Southern tip of the state of New York. It is also known as one of the world’s largest natural harbors. New York City consists of five boroughs, each of which is a separated country of New York State and has 12^th largest GDP in the world. Some of the famous tourist spot in New York are Central Park, Statue of Liberty, Times Square, Empire State Building, High Line, Brooklyn Bridge, Rockefeller Center, Metropolitan Museum of Art, Grand Central Terminal, Bryant Park, Coney Island, Chinatown, Washington Square Park, Madison Square Garden, Staten Island Ferry, Central Park Zoo, Liberty Island etc. This conference also promises you to fill with good memories at New York with its attractions.

Conference Highlights

Parkinson’s disease

Epidemiology of Parkinson’s disease

Neurocognitive and Neuromuscular Disorders

Alzheimer's Disease & Dementia

Risk factors of Parkinson’s disease

Diagnostic and Neuroimaging for Parkinson’s disease

Pathophysiology and pharmacology

Parkinson’s disease: Complications

Managing life with Parkinson’s disease

Novel Insights and therapeutics for Parkinson’s disease

Neural Transplantation

Paediatric Movement disorders

Major Associations around the globe:

Around 25 associations of Parkinson Disease are there in USA

Parkinson Association of the Rockies
Brian Grant Foundation
The Michael J. Fox Foundation
The Foundation for Mitochondrial Medicine
The International Parkinson and Movement Disorder Society
Parkinson Alliance
Parkinson's Action Network (PAN)
Bachmann-Strauss Dystonia & Parkinson Foundation
Parkinson's Resource Organization
International Association of Parkinsonism
Booth Gardner Parkinson’s Care Center
Canadian Movement Disorders Group
Dallas area Parkinsonism Society
Indian Parkinson Foundation- The Climb
New Mexico Parkinson’s Disease Coalition
Wisconsis Parkinsons Foundation

Top universities 500 globally working in the field of Parkinson Disease

University of Bath
The University of Queensland
University of Bristol
University of Cambridge
The Imperial College of Science and Medicine
Duke University
University of Milan
Karolinska Institute
University of Hamburg
The University of Edinburgh
University of Munich
University of Rochester
University of Zurich
Leiden University
University of Bristol
University of Helsinki
Uppsala University
University of Freiburg
University of Frankfurt
University of Chicago Medicine

Top universities in USA working in the field of Parkinson Disease

University of California
University of Kansas Medical Center
University of South Alabama
University of Florida
University of Miami
Georgia Health Sciences University
Emory University
Northwestern University Movement Disorders Center
Johns Hopkins Parkinson's Disease&Movement Disorders Center
New York University Langone Medical Center
University of Rochester Medical Center
Duke University Medical Center
University of North Carolina
Oregon Health & Science University Parkinson Center of Oregon
University of Pennsylvania
Vanderbilt University Medical Center
Baylor College of Medicine

Top Universities in New York

New York University

Columbia University

Fordham University

Pace University

St. John's University

Industries Associated with Parkinson Research

Dainippon Sumitomo Pharma
BioSante Pharmaceuticals
GlaxoSmithKline (GSK)
Boehringer Ingelheim

Parkinson’s 2018 are a specially designed cluster conference which will probably unite brilliant personalities to give talks that are thought focused, and on a broad assortment of subjects associated with Parkinson’s disease and Movement Disorders, to encourage learning, inspiration and ponder – and incite discussions that matter.

Benefits to Speakers:

· IOCM Certificate

· Abstracts will be published with DOI number by Cross Ref

· Handbook & Conference kits

· Website perceivability to more than 35K guests in less than 6 months

· Provocative Symposia's and Workshops

· One on One Meeting with Eminent Speakers

· Unparalleled opportunity to give presentations and network with other key opinion leaders in the field.

· Live Streaming of the gathering

· Get worldwide acknowledgement to your profile and Research

· Keynote sessions by world's most famous scientists

· Publish your compositions in the particular supporting International Journals

· Access to Preconference Workshops

· Group Registration Benefits at the conference

· Research Oriented Presentations at our Gatherings

· Encounter world class services and friendliness at the meeting

Benefits to Delegates:

· Participation Certifications

· To sharpen their skills: Delegates can analyse new ideas and procedures to make themselves extra powerful towards their work.

· Meet experts and influencers face-to-face

· The opportunity in an effort to blend and mingle, shape new relationships and toughen existing ones.

· Grow: Conference will offer a unique convergence of networking, gaining knowledge of and fun right into a single package

· Conference attendance inspires, rejuvenates, and energizes delegates

· Networking and informal sharing among colleagues

· Enjoy the alluring city environment at conference venue

· Best Hospitality services at our conference

1st round of abstract submission: Jauary 10, 2018

2nd round of abstract submission: March 14, 2018

3rd round of abstract submission: June 23, 2018

Avail Early bird registration benefits on or before August 2018

Avail group participation discounts on more than 5 participants

Time duration for each category:

Keynote Speech: 40-45 minutes

Oral/ Plenary Speech: 30-35 minutes

Workshop: 60 minutes

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	October 19-20, 2018
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed	Day 1
Poster Opportunity Closed	Click Here to View